Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
4-S-chondroitin sulfate + H2O
?
6-S-chondroitin sulfate + H2O
?
chondroitin + H2O
GlcAbeta(1-3)GalNAcbeta(1-4)GlcAbeta(1-3)GalNAc + ?
chondroitin 4-sulfate + H2O
?
chondroitin 6-sulfate + H2O
?
chondroitin B sulfate + H2O
?
very little hydrolase activity towards chondroitin sulfate B (dermatan sulfate)
-
-
?
chondroitin sulfate + H2O
?
chondroitin sulfate A + H2O
?
chondroitin sulfate A + H2O
oligosaccharides + ?
chondroitin sulfate B + H2O
?
chondroitin sulfate C + H2O
?
chondroitin sulfate D + H2O
?
chondroitin sulfate-rich proteoglycan + H2O
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
hyaluronan + H2O
hexasaccharides + tetrasaccharides
-
absolutely specific for
main products, with N-acetyl-beta-D-glucosamine at the reducing end, cleavage of beta-1,4-glycosidic linkage, not beta-1,3-glycosidic linkage
?
hyaluronan + H2O
hyaluronan oligomers
hyaluronan + H2O
N-acetylglucosamine + D-glucuronate + ?
-
complete degradation, absolutely specific for
-
?
hyaluronan + H2O
oligosaccharides
-
specific cleavage of beta-1,4-glucosidic linkages
-
?
hyaluronan + H2O
tetraoligosaccharides + hexaoligosaccharides
hyaluronan + H2O
tetrasaccharides units of hyaluronan
hyaluronan decasaccharide + H2O
hyaluronan tetrasaccharide + hyaluronan hexasaccharide + hyaluronan octasaccharide +
-
-
31.5% hyaluronan tetrasaccharide, 48.3% hyaluronan hexasaccharide, 14.7% hyaluronan octasaccharide, 5.5% hyaluronan decasaccharide
-
?
hyaluronan octasaccharide + H2O
hyaluronan tetrasaccharide + hyaluronan hexasaccharide
-
-
46.8% hyaluronan tetrasaccharide, 32.7% hyaluronan hexasaccharide, 20.5% hyaluronan octasaccharide. Enzyme generates a disaccharide intermediate from hyaluronan oligosaccharide, the majority of which is transferred to the nonreducing ends of other oligosaccharides, only traces being released as free disaccharide. When hyaluronan octasaccharide, with an unsaturated glucuronic acid at the nonreducing end, is used as a substrate, only a tetrasaccharide product is detected by HPLC. MS shows that the product is a mixture of equal amounts of two tetrasaccharides, one with and the other without the unsaturated glucuronic acid. This suggests that, in the case of substrates with a double bond at the nonreducing end, a tetrasaccharide is cleaved off instead of a disaccharide
-
?
hyaluronan oligosaccharides + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
-
specific cleavage of beta-1,4-glucosidic linkages
-
?
hyaluronate + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
hyaluronate + H2O
oligosaccharides
-
from human umbilical cord
establishing of a rapid, sensitive PAGE method for analysis of hyaluronan oligosaccharides
?
hyaluronic acid + H2O
hyaluronic acid oligomers
hyaluronic acid + H2O
hyaluronic acid tetrasaccharides + ?
hyaluronic acid + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
?
hyaluronic acid from Streptococcus pyogenes (35 kDa) + H2O
?
hyaluronic acid hexasaccharide + H2O
?
-
not only lower oligosaccharides, but also higher oligosaccharides are produced, transglycosylation activity, multiple disaccharide units are rapidly transferred from one substrate molecule to another
-
-
r
hyaluronic acid hexasaccharide + H2O
hyaluronic acid octasaccharide + hyaluronic acid disaccharide + hyaluronic acid tetrasaccharide
-
hydrolysis in disaccharide units, transglycosylation activity, smallest substrate
-
r
hyaluronic acid octasaccharosyl-pyridylaminoside + H2O
hexasaccharosyl-pyridylaminoside + hyaluronic acid disaccharide
-
smallest substrate, hydrolysis of even-numbered oligosaccharides with glucuronic acid at the non-reducing terminal by successive removal of disaccharide units from the non-reducing terminal
-
?
hyaluronic acid-rich cumulus matrix + H2O
?
sodium hyaluronate + H2O
?
-
100% activity
-
-
?
additional information
?
-
4-S-chondroitin sulfate + H2O
?
-
-
-
?
4-S-chondroitin sulfate + H2O
?
-
-
-
?
4-S-chondroitin sulfate + H2O
?
EU152302
-
-
-
?
6-S-chondroitin sulfate + H2O
?
the enzyme is capable of degrading chondroitin sulfate C at a rate of around 40% compared to its hyaluronidase activity
-
-
?
6-S-chondroitin sulfate + H2O
?
-
-
-
?
6-S-chondroitin sulfate + H2O
?
EU152302
the enzyme is capable of degrading CS-C at a rate of around 40% compared to its hyaluronidase activity
-
-
?
chitin + H2O
?
-
-
-
-
?
chitin + H2O
?
-
12 h incubation
-
-
?
chondroitin + H2O
?
-
-
-
-
?
chondroitin + H2O
?
-
-
-
-
?
chondroitin + H2O
GlcAbeta(1-3)GalNAcbeta(1-4)GlcAbeta(1-3)GalNAc + ?
-
-
main product
-
ir
chondroitin + H2O
GlcAbeta(1-3)GalNAcbeta(1-4)GlcAbeta(1-3)GalNAc + ?
-
-
main product
-
ir
chondroitin 4-sulfate + H2O
?
-
28% activity compared to sodium hyaluronate
-
-
?
chondroitin 4-sulfate + H2O
?
-
-
-
-
?
chondroitin 4-sulfate + H2O
?
-
-
-
?
chondroitin 6-sulfate + H2O
?
-
19% activity compared to sodium hyaluronate
-
-
?
chondroitin 6-sulfate + H2O
?
-
-
-
-
?
chondroitin 6-sulfate + H2O
?
-
-
-
?
chondroitin sulfate + H2O
?
-
-
-
-
?
chondroitin sulfate + H2O
?
-
-
-
-
?
chondroitin sulfate + H2O
?
-
-
-
-
?
chondroitin sulfate + H2O
?
-
-
-
-
?
chondroitin sulfate + H2O
?
-
-
-
-
?
chondroitin sulfate + H2O
?
-
-
-
-
?
chondroitin sulfate + H2O
?
-
-
-
-
?
chondroitin sulfate + H2O
?
Eusimulium latipes
-
-
-
-
?
chondroitin sulfate + H2O
?
-
-
-
-
?
chondroitin sulfate + H2O
?
-
-
-
?
chondroitin sulfate + H2O
?
-
-
-
-
?
chondroitin sulfate + H2O
?
-
-
-
-
?
chondroitin sulfate + H2O
?
-
-
-
-
?
chondroitin sulfate A + H2O
?
-
-
-
?
chondroitin sulfate A + H2O
?
-
poor substrate
-
-
?
chondroitin sulfate A + H2O
?
-
-
-
-
?
chondroitin sulfate A + H2O
oligosaccharides + ?
-
-
-
-
?
chondroitin sulfate A + H2O
oligosaccharides + ?
-
acting at the same rate as with hyaluronic acid
-
-
?
chondroitin sulfate A + H2O
oligosaccharides + ?
-
production of even-numbered oligosaccharides only produced by lysosomal hyaluronidase
-
?
chondroitin sulfate A + H2O
oligosaccharides + ?
-
-
-
-
?
chondroitin sulfate B + H2O
?
very little hydrolase activity
-
-
?
chondroitin sulfate B + H2O
?
EU152302
very little hydrolase activity
-
-
?
chondroitin sulfate C + H2O
?
-
-
-
?
chondroitin sulfate C + H2O
?
-
acting at the same rate as with hyaluronic acid
-
?
chondroitin sulfate C + H2O
?
-
-
-
-
?
chondroitin sulfate C + H2O
?
-
-
-
-
?
chondroitin sulfate D + H2O
?
-
-
-
-
?
chondroitin sulfate D + H2O
?
-
-
-
-
?
chondroitin sulfate-rich proteoglycan + H2O
?
-
from bovine nasal cartilage
-
?
chondroitin sulfate-rich proteoglycan + H2O
?
-
from bovine nasal cartilage
-
?
chondroitin sulfate-rich proteoglycan + H2O
?
-
from bovine nasal cartilage
-
?
chondroitin sulfate-rich proteoglycan + H2O
?
-
from bovine nasal cartilage
-
?
chondroitin sulfate-rich proteoglycan + H2O
?
-
from bovine nasal cartilage
-
?
chondroitin sulfate-rich proteoglycan + H2O
?
-
from bovine nasal cartilage
-
?
chondroitin sulfate-rich proteoglycan + H2O
?
-
from bovine nasal cartilage
-
?
chondroitin sulfate-rich proteoglycan + H2O
?
-
from bovine nasal cartilage
-
?
chondroitin sulfate-rich proteoglycan + H2O
?
-
from bovine nasal cartilage
-
?
chondroitin sulfate-rich proteoglycan + H2O
?
-
from bovine nasal cartilage
-
?
chondroitin sulfate-rich proteoglycan + H2O
?
-
from bovine nasal cartilage
-
?
chondroitin sulfate-rich proteoglycan + H2O
?
-
from bovine nasal cartilage
-
?
chondroitin sulfate-rich proteoglycan + H2O
?
-
from bovine nasal cartilage
-
?
chondroitin sulfate-rich proteoglycan + H2O
?
-
from bovine nasal cartilage
-
?
chondroitin sulfate-rich proteoglycan + H2O
?
Vipera elegans
-
from bovine nasal cartilage
-
?
dermatan + H2O
?
-
7% activity compared to sodium hyaluronate
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
from Streptococcus zooepidemicus, degradation
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
from Streptococcus zooepidemicus, degradation
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
highly specific substrate with 10fold higher activity compared to chondroitin 4-sulfate, chondroitin 6-sulfate, or dermatan
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
absolute specificity for hyaluronan
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
from Streptococcus zooepidemicus
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
from Streptococcus zooepidemicus, degradation
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
from Streptococcus zooepidemicus, degradation
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
-
?
hyaluronan + H2O
?
-
-
-
-
?
hyaluronan + H2O
?
-
a fluorescent substrate (FRET-HA) to quantitatively assess hyaluronidase activity is developed. Hyaluronan (HA)is dual labeled with fluorescein amine and rhodamine B amine. The fluorescein amine fluorescence signal is significantly quenched and the rhodamine B amine signal is significantly enhanced due to fluorescence resonance energy transfer (FRET). In the presence of bovine testes hyaluronidase, cleavage of HA disrupts FRET, resulting in a loss of the fluorescein amine quenching that is dependent on both enzyme concentration and time. Increase in the fluorescein amine signal can be conveniently monitored in both noncontinuous and continuous fashions
-
-
?
hyaluronan + H2O
?
-
HPLC and MS analyses of the products reveal the existance of oligosaccharides which are not produced under hydrolysis conditions, but during transglycosylation by the enzyme, suggesting that a novel enzyme is present as a contaminant in commercial BTH, which acts as an N-deacetylase of N-acetylglucosamine at the reducing terminal of hyaluronan oligosaccharides
-
-
?
hyaluronan + H2O
?
-
hyaluronan fragments are used with a molar mass ranging from 800 g/mol to 250000 g/mol and native hyaluronan to study the influence of the chain length of hyaluronan on the kinetics of its HAase-catalyzed hydrolysis. The initial hydrolysis rate strongly varies with hyaluronan chain length. The ability of HA chains to form an efficient enzyme-substrate complex is maximum for hyaluronan molar masses ranging from 3000 to 20000 g/mol. Shorter hyaluronan chains are too short to form a stable complex and longer hyaluronan chains encounter difficulties in forming a complex, due to steric hindrance. As the chain length decreases the HAase increasingly catalyses transglycosylation rather than hydrolysis. Two hyaluronan chain populations, corresponding to hyaluronan chain molar masses lower and higher than approximately 20000 g/mol are identified and related to the bi-exponential character
-
-
?
hyaluronan + H2O
?
-
-
-
?
hyaluronan + H2O
?
-
-
-
-
?
hyaluronan + H2O
?
-
-
-
-
?
hyaluronan + H2O
?
-
-
-
-
?
hyaluronan + H2O
?
-
-
-
-
?
hyaluronan + H2O
?
Eusimulium latipes
-
-
-
-
?
hyaluronan + H2O
?
-
-
-
?
hyaluronan + H2O
?
-
-
-
?
hyaluronan + H2O
?
-
-
-
?
hyaluronan + H2O
?
-
-
-
?
hyaluronan + H2O
?
-
-
-
?
hyaluronan + H2O
?
complete degradation, absolutely specific for
-
?
hyaluronan + H2O
?
wild-type isozyme HYAL1 sequence, amino acid residues 301-330, is critical for hyaluronidase activity
-
?
hyaluronan + H2O
?
-
hyaluronan deposition and turnover is even more abundant and more rapid in malignant tissues. The proportion of low molecular weight (LMW) fragments of HA is greater in tumors and tumor patients than in the normal
-
-
?
hyaluronan + H2O
?
human platelets degrade the proinflammatory matrix hyaluronan through the activity of HYAL2 and platelet activation causes the immediate translocation of HYAL2 from a distinct population of alpha-granules to platelet surfaces where it exerts its catalytic activity
-
-
?
hyaluronan + H2O
?
-
-
-
?
hyaluronan + H2O
?
-
-
-
?
hyaluronan + H2O
?
-
-
-
-
?
hyaluronan + H2O
?
-
-
-
-
?
hyaluronan + H2O
?
-
-
-
-
?
hyaluronan + H2O
?
-
-
-
?
hyaluronan + H2O
?
-
catalyzes the endolytic hydrolysis of beta-1,4 glycosidic linkages in hyaluronan. Products are saturated hyaluronan-disaccharides
-
?
hyaluronan + H2O
?
complete degradation, absolutely specific for
-
?
hyaluronan + H2O
hyaluronan oligomers
-
-
-
?
hyaluronan + H2O
hyaluronan oligomers
-
-
-
-
?
hyaluronan + H2O
hyaluronan oligomers
-
-
-
-
?
hyaluronan + H2O
hyaluronan oligomers
-
the enzyme is required for fertility facilitating the penetration of sperm through the cumulus mass in the ovum
-
-
?
hyaluronan + H2O
hyaluronan oligomers
-
the enzyme shows low activity, degradation
-
-
?
hyaluronan + H2O
hyaluronan oligomers
-
-
-
-
?
hyaluronan + H2O
hyaluronan oligomers
-
human skin sections
-
-
?
hyaluronan + H2O
hyaluronan oligomers
-
isozyme NNH2 shows endoglycosidase activity, absolute specific for in vitro, substrate from human skin
-
-
?
hyaluronan + H2O
hyaluronan oligomers
Palamneus gravimanus
-
-
-
-
?
hyaluronan + H2O
hyaluronan oligomers
human substrate
-
-
?
hyaluronan + H2O
tetraoligosaccharides + hexaoligosaccharides
-
-
-
r
hyaluronan + H2O
tetraoligosaccharides + hexaoligosaccharides
-
-
after complete digestion
?
hyaluronan + H2O
tetrasaccharides units of hyaluronan
-
absolutely specific for
-
-
?
hyaluronan + H2O
tetrasaccharides units of hyaluronan
-
absolutely specific for, cleavage of beta-1,4-glycosidic linkages, of human skin, extracellular matrix
-
-
?
hyaluronate + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
?
hyaluronate + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
?
hyaluronate + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
from umbilical cord
-
?
hyaluronate + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
from umbilical cord
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
-
-
?
hyaluronic acid + H2O
?
-
from rooster comb
-
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
from rooster comb
-
-
?
hyaluronic acid + H2O
?
the Asn-X-Ser/Thr sequence is essential for this activity
-
-
?
hyaluronic acid + H2O
?
-
degradation in human skin, human muscle, chick embryo
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
spreading factor for dermonecrosis
-
-
?
hyaluronic acid + H2O
?
-
spreading factor for dermonecrosis
-
-
?
hyaluronic acid + H2O
?
-
degradation in human skin, human muscle, chick embryo
-
?
hyaluronic acid + H2O
?
-
degradation in human skin, human muscle, chick embryo
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
degradation in human skin, human muscle, chick embryo
-
?
hyaluronic acid + H2O
?
-
degradation in human skin, human muscle, chick embryo
-
?
hyaluronic acid + H2O
?
-
degradation in human skin, human muscle, chick embryo
-
?
hyaluronic acid + H2O
?
-
degradation in human skin, human muscle, chick embryo
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
-
-
?
hyaluronic acid + H2O
?
-
-
-
?
hyaluronic acid + H2O
?
-
involved in inflammatory reactions, exists as inactive form activated by metal ions
-
-
?
hyaluronic acid + H2O
?
-
important in hyaluronate catabolism in the vitreous
-
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
-
-
?
hyaluronic acid + H2O
?
-
-
-
?
hyaluronic acid + H2O
?
-
two isoforms necessary for penetration of extracellular vestments surrounding eggs prior fertilization
-
-
?
hyaluronic acid + H2O
?
-
degradation in human skin, human muscle, chick embryo
-
?
hyaluronic acid + H2O
?
-
degradation in human skin, human muscle, chick embryo
-
?
hyaluronic acid + H2O
?
-
degradation in human skin, human muscle, chick embryo
-
?
hyaluronic acid + H2O
?
-
degradation in human skin, human muscle, chick embryo
-
?
hyaluronic acid + H2O
?
-
endo-mucopolysaccharidase hydrolysing acid mucopolysaccharides from connective tissue and chondroitin-sulfate in cartilage
-
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
degradation in human skin, human muscle, chick embryo
-
?
hyaluronic acid + H2O
?
-
degradation in human skin, human muscle, chick embryo
-
?
hyaluronic acid + H2O
?
-
degradation in human skin, human muscle, chick embryo
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
spreading factor for dermonecrosis
-
-
?
hyaluronic acid + H2O
?
-
-
-
?
hyaluronic acid + H2O
?
Vipera elegans
-
degradation in human skin, human muscle, chick embryo
-
?
hyaluronic acid + H2O
hyaluronic acid oligomers
-
-
-
?
hyaluronic acid + H2O
hyaluronic acid oligomers
-
-
-
?
hyaluronic acid + H2O
hyaluronic acid oligomers
-
-
-
?
hyaluronic acid + H2O
hyaluronic acid oligomers
-
-
-
?
hyaluronic acid + H2O
hyaluronic acid oligomers
-
-
-
?
hyaluronic acid + H2O
hyaluronic acid oligomers
-
-
-
?
hyaluronic acid + H2O
hyaluronic acid oligomers
-
-
-
?
hyaluronic acid + H2O
hyaluronic acid oligomers
-
-
-
?
hyaluronic acid + H2O
hyaluronic acid oligomers
-
-
-
?
hyaluronic acid + H2O
hyaluronic acid oligomers
-
-
-
?
hyaluronic acid + H2O
hyaluronic acid oligomers
-
-
-
?
hyaluronic acid + H2O
hyaluronic acid oligomers
-
-
-
?
hyaluronic acid + H2O
hyaluronic acid tetrasaccharides + ?
-
complete hydrolysis
-
?
hyaluronic acid + H2O
hyaluronic acid tetrasaccharides + ?
-
complete hydrolysis
-
?
hyaluronic acid from Streptococcus pyogenes (35 kDa) + H2O
?
-
-
-
-
?
hyaluronic acid from Streptococcus pyogenes (35 kDa) + H2O
?
-
-
-
-
?
hyaluronic acid-rich cumulus matrix + H2O
?
-
-
-
?
hyaluronic acid-rich cumulus matrix + H2O
?
-
investment of oocyte during sperm invasion
-
?
additional information
?
-
-
no activity with chondroitin 4-sulfate, chondroitin 6-sulfate, dermatan sulfate, chondroitin sulfates D and E, and heparin, no activity with 4-nitrophenyl-beta-glucuronide or 4-nitrophenyl-N-acetyl-beta-glucoaminide
-
?
additional information
?
-
the enzyme is a major allergen of bee venom which can induce serious, occasionally fatal, systemic IgE-mediated anaphylactic reactions in humans
-
?
additional information
?
-
-
hyaluronan is degraded by L-ascorbic acid, D-isoascorbic acid, and dehydroascorbic acid themselves, only slightly by L-gulonic-gamma-lactone, D-saccharic-1,4-lactone, and alpha-D-glucoheptonic-gamma-lactone
-
?
additional information
?
-
-
simulation of progress of product distribution from short oligosaccharides with the Monte Carlo method using the probalistic model
-
?
additional information
?
-
-
enzyme additionally catalyzes transglycosylation reactions of chondroitin sulfates. Barium salt of chondroitin sulfates enhances transglycosylation, the zinc salt of chondroitin sulfates inhibits transglycosylation
-
-
?
additional information
?
-
-
minimum substrate for bovine testicular hyaluronidase is the hyaluronan hexasaccharide
-
-
?
additional information
?
-
-
chondroitin, chondroitin sulfate A, chondroitin sulfate B, chondroitin sulfate C, chondroitin sulfate D, heparin, and chitosan are no substrates
-
-
?
additional information
?
-
-
the splice variant is enzymatically inactive
-
?
additional information
?
-
the splice variant is enzymatically inactive
-
?
additional information
?
-
the splice variant is enzymatically inactive
-
?
additional information
?
-
-
alternative splicing controls the cellular expression of enzymatically active hyaluronidase
-
?
additional information
?
-
alternative splicing controls the cellular expression of enzymatically active hyaluronidase
-
?
additional information
?
-
alternative splicing controls the cellular expression of enzymatically active hyaluronidase
-
?
additional information
?
-
-
increased concentration of HYAL1-type enzyme correlates with tumour progression and is a marker for grade (G) 2 or 3 bladder cancer
-
?
additional information
?
-
increased concentration of HYAL1-type enzyme correlates with tumour progression and is a marker for grade (G) 2 or 3 bladder cancer
-
?
additional information
?
-
increased concentration of HYAL1-type enzyme correlates with tumour progression and is a marker for grade (G) 2 or 3 bladder cancer
-
?
additional information
?
-
-
HPH-20 or SPAM1, sperm adhesion molecule 1, is a bifunctional enzyme, which is also an adhesion molecule with binding properties to the cumulus mass surrounding the ovum
-
-
?
additional information
?
-
Hyal 1 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
Hyal 1 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
Hyal 1 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
-
Hyal 1 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
Hyal 2 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
Hyal 2 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
Hyal 2 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
-
Hyal 2 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
Hyal 3 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
Hyal 3 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
Hyal 3 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
-
Hyal 3 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
this gene may play an important role in the development of lung and renal malignancies, the expression of hyaluronidase-1 or hyaluronidase-2 suppresses tumour growth in vivo but not in vitro, HYAL2 inhibits experimental lung metastases in nu/nu mice
-
-
?
additional information
?
-
this gene may play an important role in the development of lung and renal malignancies, the expression of hyaluronidase-1 or hyaluronidase-2 suppresses tumour growth in vivo but not in vitro, HYAL2 inhibits experimental lung metastases in nu/nu mice
-
-
?
additional information
?
-
-
this gene may play an important role in the development of lung and renal malignancies, the expression of hyaluronidase-1 or hyaluronidase-2 suppresses tumour growth in vivo but not in vitro, HYAL2 inhibits experimental lung metastases in nu/nu mice
-
-
?
additional information
?
-
this gene may play an important role in the development of lung and renal malignancies, the expression of hyaluronidase-1 suppresses tumour growth in vivo but not in vitro
-
-
?
additional information
?
-
this gene may play an important role in the development of lung and renal malignancies, the expression of hyaluronidase-1 suppresses tumour growth in vivo but not in vitro
-
-
?
additional information
?
-
-
this gene may play an important role in the development of lung and renal malignancies, the expression of hyaluronidase-1 suppresses tumour growth in vivo but not in vitro
-
-
?
additional information
?
-
among hyaluronidases Hyal-1 to Hyal-4, only rHuHyal-4 exhibits chondroitinase activity with both 6-S-chondroitin sulfate and 4-S-chondroitin sulfate as standard substrates
-
-
?
additional information
?
-
among hyaluronidases Hyal-1 to Hyal-4, only rHuHyal-4 exhibits chondroitinase activity with both 6-S-chondroitin sulfate and 4-S-chondroitin sulfate as standard substrates
-
-
?
additional information
?
-
among hyaluronidases Hyal-1 to Hyal-4, only rHuHyal-4 exhibits chondroitinase activity with both 6-S-chondroitin sulfate and 4-S-chondroitin sulfate as standard substrates
-
-
?
additional information
?
-
among hyaluronidases Hyal-1 to Hyal-4, only rHuHyal-4 exhibits chondroitinase activity with both 6-S-chondroitin sulfate and 4-S-chondroitin sulfate as standard substrates
-
-
?
additional information
?
-
-
among hyaluronidases Hyal-1 to Hyal-4, only rHuHyal-4 exhibits chondroitinase activity with both 6-S-chondroitin sulfate and 4-S-chondroitin sulfate as standard substrates
-
-
?
additional information
?
-
-
the enzyme strongly prefers D-glucuronic acid-(2-O-sulfate)-GalNAc(6-O-sulfate)-containing sequences typical in chondroitin sulfate D
-
-
?
additional information
?
-
-
the jaagsiekte sheep retrovirus receptor Hyal2 interacts specifically with the virus particles of the amphotropic murine leukemia virus-pseudotype vectors/JSRV-pseudotype vector envelope protein, binding kinetics, the binding inhibits virus entry into cells, overview
-
-
?
additional information
?
-
-
does not hydrolyze chondroitin sulfate B, heparin, or heparan sulfate
-
-
?
additional information
?
-
no activity with dermatan sulfate and heparan sulfate
-
-
?
additional information
?
-
-
no activity with dermatan sulfate and heparan sulfate
-
-
?
additional information
?
-
-
CD44-mediated specific role of certain populations of testicular enzyme in the induction of angiogenesis
-
?
additional information
?
-
-
enzyme activity in serum from tumour-bearing mice, e.g. H460M or SA87 cell grafted mice, is increased, the level is corrsponding to the tumour mass, not in serum from CB193 cell grafted mice
-
?
additional information
?
-
-
the enzyme depolymerizes various chondroitin sulfate isoforms to a similar extent, suggesting broad substrate specificity
-
-
?
additional information
?
-
-
isozyme NNH2 is nontoxic, but indirectly potentiates the hemorrhagic activity of hemorrhagic complex-I
-
-
?
additional information
?
-
-
the enzyme indirectly potentiates the myotoxicity of VRV-PL-VIII, a phospholipolytic myotoxin, and also the hemorrhagic potency of a hemorrhagic complex-I
-
-
?
additional information
?
-
-
no activity with chondroitin sulfates, heparin, and different chitosans
-
-
?
additional information
?
-
-
no activity with chondroitin sulfates, heparin, chitosan, 4-nitrophenyl-N-acetyl-beta-D-glucosaminide, or 4-nitrophenyl-beta-D-glucuronide
-
-
?
additional information
?
-
no substrate: chondroitin
-
-
?
additional information
?
-
-
no substrate: chondroitin
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
hyaluronan + H2O
hyaluronan oligomers
hyaluronan + H2O
tetrasaccharides units of hyaluronan
-
absolutely specific for
-
-
?
hyaluronate + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
?
hyaluronic acid-rich cumulus matrix + H2O
?
-
investment of oocyte during sperm invasion
-
?
additional information
?
-
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
highly specific substrate with 10fold higher activity compared to chondroitin 4-sulfate, chondroitin 6-sulfate, or dermatan
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
-
?
hyaluronan + 2 H2O
N-acetyl-beta-D-glucosamine + D-glucuronate + ?
-
-
-
-
?
hyaluronan + H2O
?
complete degradation, absolutely specific for
-
?
hyaluronan + H2O
?
human platelets degrade the proinflammatory matrix hyaluronan through the activity of HYAL2 and platelet activation causes the immediate translocation of HYAL2 from a distinct population of alpha-granules to platelet surfaces where it exerts its catalytic activity
-
-
?
hyaluronan + H2O
hyaluronan oligomers
-
-
-
?
hyaluronan + H2O
hyaluronan oligomers
-
-
-
-
?
hyaluronan + H2O
hyaluronan oligomers
-
the enzyme is required for fertility facilitating the penetration of sperm through the cumulus mass in the ovum
-
-
?
hyaluronan + H2O
hyaluronan oligomers
-
-
-
-
?
hyaluronan + H2O
hyaluronan oligomers
-
human skin sections
-
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
spreading factor for dermonecrosis
-
-
?
hyaluronic acid + H2O
?
-
spreading factor for dermonecrosis
-
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
involved in inflammatory reactions, exists as inactive form activated by metal ions
-
-
?
hyaluronic acid + H2O
?
-
important in hyaluronate catabolism in the vitreous
-
-
?
hyaluronic acid + H2O
?
-
two isoforms necessary for penetration of extracellular vestments surrounding eggs prior fertilization
-
-
?
hyaluronic acid + H2O
?
-
endo-mucopolysaccharidase hydrolysing acid mucopolysaccharides from connective tissue and chondroitin-sulfate in cartilage
-
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
-
-
-
?
hyaluronic acid + H2O
?
-
spreading factor for dermonecrosis
-
-
?
additional information
?
-
the enzyme is a major allergen of bee venom which can induce serious, occasionally fatal, systemic IgE-mediated anaphylactic reactions in humans
-
?
additional information
?
-
-
alternative splicing controls the cellular expression of enzymatically active hyaluronidase
-
?
additional information
?
-
alternative splicing controls the cellular expression of enzymatically active hyaluronidase
-
?
additional information
?
-
alternative splicing controls the cellular expression of enzymatically active hyaluronidase
-
?
additional information
?
-
-
increased concentration of HYAL1-type enzyme correlates with tumour progression and is a marker for grade (G) 2 or 3 bladder cancer
-
?
additional information
?
-
increased concentration of HYAL1-type enzyme correlates with tumour progression and is a marker for grade (G) 2 or 3 bladder cancer
-
?
additional information
?
-
increased concentration of HYAL1-type enzyme correlates with tumour progression and is a marker for grade (G) 2 or 3 bladder cancer
-
?
additional information
?
-
-
HPH-20 or SPAM1, sperm adhesion molecule 1, is a bifunctional enzyme, which is also an adhesion molecule with binding properties to the cumulus mass surrounding the ovum
-
-
?
additional information
?
-
Hyal 1 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
Hyal 1 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
Hyal 1 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
-
Hyal 1 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
Hyal 2 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
Hyal 2 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
Hyal 2 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
-
Hyal 2 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
Hyal 3 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
Hyal 3 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
Hyal 3 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
-
Hyal 3 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
?
additional information
?
-
this gene may play an important role in the development of lung and renal malignancies, the expression of hyaluronidase-1 or hyaluronidase-2 suppresses tumour growth in vivo but not in vitro, HYAL2 inhibits experimental lung metastases in nu/nu mice
-
-
?
additional information
?
-
this gene may play an important role in the development of lung and renal malignancies, the expression of hyaluronidase-1 or hyaluronidase-2 suppresses tumour growth in vivo but not in vitro, HYAL2 inhibits experimental lung metastases in nu/nu mice
-
-
?
additional information
?
-
-
this gene may play an important role in the development of lung and renal malignancies, the expression of hyaluronidase-1 or hyaluronidase-2 suppresses tumour growth in vivo but not in vitro, HYAL2 inhibits experimental lung metastases in nu/nu mice
-
-
?
additional information
?
-
this gene may play an important role in the development of lung and renal malignancies, the expression of hyaluronidase-1 suppresses tumour growth in vivo but not in vitro
-
-
?
additional information
?
-
this gene may play an important role in the development of lung and renal malignancies, the expression of hyaluronidase-1 suppresses tumour growth in vivo but not in vitro
-
-
?
additional information
?
-
-
this gene may play an important role in the development of lung and renal malignancies, the expression of hyaluronidase-1 suppresses tumour growth in vivo but not in vitro
-
-
?
additional information
?
-
-
CD44-mediated specific role of certain populations of testicular enzyme in the induction of angiogenesis
-
?
additional information
?
-
-
enzyme activity in serum from tumour-bearing mice, e.g. H460M or SA87 cell grafted mice, is increased, the level is corrsponding to the tumour mass, not in serum from CB193 cell grafted mice
-
?
additional information
?
-
-
isozyme NNH2 is nontoxic, but indirectly potentiates the hemorrhagic activity of hemorrhagic complex-I
-
-
?
additional information
?
-
-
the enzyme indirectly potentiates the myotoxicity of VRV-PL-VIII, a phospholipolytic myotoxin, and also the hemorrhagic potency of a hemorrhagic complex-I
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-2-hydroxy-2-(4-hydroxybenzyl)-3-[[(2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-2-hydroxy-2-(4-hydroxybenzyl)-3-[[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-3-[[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-2-hydroxy-2-(4-hydroxybenzyl)butanedioic acid
-
-
(2R,3S)-3-[[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]oxy]-2-hydroxy-2-(4-hydroxybenzyl)butanedioic acid
-
-
(2S)-2-(3,4-dimethoxy-5-oxo-2,5-dihydrofuran-2-yl)-2-hydroxyethyl hexadecaneperoxoate
-
inactive at concentrations less than 0.2 mM, at pH 5.0
(2S)-2-[3,4-bis(benzyloxy)-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl hexadecaneperoxoate
-
inactive at concentrations less than 0.2 mM, at pH 5.0
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-21-cyclohexyl-28-hydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-23,28-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-22-[[(2Z)-2-methylbut-2-enoyl]oxy]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-22-[(2-methylbutanoyl)oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic aci
-
-
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosidur
-
-
(3beta,16alpha,21beta,22alpha)-16,28-bis(acetyloxy)-22-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,28-bis(acetyloxy)-22-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic a
-
-
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-22-[[(2E)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosi
-
-
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosi
-
-
(3beta,16alpha,21beta,22alpha)-22-(acetyloxy)-16,28-dihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-22-(acetyloxy)-16,28-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-28-(acetyloxy)-16,22-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-28-(acetyloxy)-21-cyclohexyl-16,22-dihydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,22alpha)-22-(cyclohexyloxy)-16,23,28-trihydroxyolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,22alpha)-22-(cyclohexyloxy)-16,28-dihydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(5R)-3,4-bis(benzyloxy)-5-(1,2-dihydroxyethyl)furan-2(5H)-one
-
inactive at concentrations less than 13 mM, at pH 5.0
(5R)-5-(1,2-dihydroxyethyl)-3,4-dimethoxyfuran-2(5H)-one
-
inactive at concentrations less than 13 mM, at pH 5.0
(7S)-7-(1,2-dihydroxyethyl)-2,3-dihydrofuro[3,4-b][1,4]dioxin-5(7H)-one
-
inactive at concentrations less than 13 mM, at pH 5.0
2-aminobenzimidazole
0.04 mM, 92% inhibition
2-hydroxy-2-[(5R)-7-oxo-2,3,5,7-tetrahydrofuro[3,4-b][1,4]dioxin-5-yl]ethyl hexadecaneperoxoate
-
inactive at concentrations less than 0.2 mM, at pH 5.0
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl ([1-[2-(benzyloxy)ethenylidene]but-2-yn-1-yl]oxy)ethaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 11-phenoxyundecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 11-[[1-(2-phenylethenylidene)but-2-yn-1-yl]oxy]undecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 2,2-dimethylpropaneperoxoate
-
inactive at concentrations less than 1.1 mM, at pH 5.0
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 3-(2-phenylethenylidene)hex-4-yneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 6-(benzyloxy)hexaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 6-phenoxyhexaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl benzenecarboperoxoate
-
33% inhibition at 1.43 mM
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl decaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl dodecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl hexadecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl hexaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl octadecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl octaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl tetradecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl tridecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl undecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl [(1-prop-1-yn-1-ylpenta-1,2-dien-1-yl)oxy]ethaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl [[1-(2-phenylethenylidene)but-2-yn-1-yl]oxy]ethaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl [[2-(2-phenylethenylidene)pent-3-yn-1-yl]oxy]ethaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl {[1-(2-phenylethenylidene)but-2-yn-1-yl]oxy}ethaneperoxoate
-
-
3-(4-methylpiperazin-1-yl)-5-phenyl-1H-indole
-
0.05 mM, 23% inhibition in stains-all assay, pH 7.0
3-amino-6-chloro-N-(diaminomethylidene)-5-[ethyl(propan-2-yl)amino]pyrazine-2-carboxamide
-
6-chloromethyluracil
0.05 mM, 94% inhibition
6-palmitoyl-L-ascorbic acid
acetylated hyaluronic acid
-
-
-
Ag+
-
82% inhibition at 0.8 mM
ascorbic acid palmitate
-
inhibition at pH 7: 99%, at pH 3.5: 99%
beta1,4-galacto-oligosaccharides
-
Br2+
0.2 M, about 40% loss of activity
-
butylated hydroxytoluene
-
-
cysteine
-
complete inhibition from 0.012-1.2 mg/ml
dehydroascorbic acid
-
weak inhibition
disodium cromoglycate
-
-
fully O-sulfonated chondroitin sulfate
-
competitive and noncompetitive mode, 50% inhibition at 0.00135 mg/ml
-
fully O-sulfonated dermatan sulfate
-
competitive and noncompetitive mode, 50% inhibition at 0.00133 mg/ml
fully O-sulfonated heparan sulfate
-
competitive and noncompetitive mode, 50% inhibition at 0.00128 mg/ml
-
fully O-sulfonated heparin
-
50% inhibition at 0.00114 mg/ml
-
fully O-sulfonated hyaluronan
-
50% inhibition at 0.00078 mg/ml
heparan O-sulfate
-
IC50 = 0.00128 mg/ml
-
heparin O-sulfate
-
IC50 = 0.00114 mg/ml, competitive and non-competitive inhibitory effects
-
hyaluronan O-sulfate
-
IC50 = 0.00078 mg/ml
hyaluronic acid
-
inhibitory at high concentrations (0.73 g/l)
isorhamnetin
-
51.04% inhibition at 0.2 mM
L-Arginine-HCl
-
8% residual activity at 1 mM
L-ascorbic acid decanoate
-
-
L-ascorbic acid dodecanoate
-
-
L-ascorbic acid tridecanoate
-
-
L-ascorbic acid undecanoate
-
-
L-cysteine
Palamneus gravimanus
-
-
myricetin 3-O-beta-D-glucopyranoside
-
-
N-(4,6-dimethylpyridin-2-yl)-(1-ethylindole-3-yl)acetamide
-
inhibition at pH 7: 3%, but at pH 3.5: 134% activation
N-(4,6-dimethylpyridin-2-yl)-[5-bromo-1-(4-methyl)indole-3-yl]carboxamide
-
inhibition at pH 7: 37%, but at pH 3.5: 117% activation
N-(4-chlorobenzyl)-1-(4-fluorobenzyl)-1H-indole-3-carboxamide
N-(4-fluorobenzyl)-1-benzyl-1H-indole-2-carboxamide
N-(pyridin-4yl)-[5-bromo-1-(4-fluorobenzyl)indole-3-yl]carboxamide
-
inhibition at pH 7: 50%, but at pH 3.5: 120% activation
N-alpha-tosyl-L-lysine chloromethyl ketone
-
nitrated hyaluronic acid
-
-
-
nordihydroguaiaretic acid
-
-
octyl 3,4-dihydroxybenzoate
-
-
octyl 3,5-dihydroxybenzoate
-
-
partially sulfated neomycin
-
partially sulfated planteose
partially sulfated verbascose
-
polymer from gentisic acid
-
-
-
quinol
-
irreversible inhibition
quinone
-
irreversible inhibition
sorghum bran
-
the ability of ethanolic extracts of bran from six cultivated varieties of Sorghum bicolor to inhibit hyaluronidase activity in vitro is assessed. Each extract inhibits hyaluronidase activity with this order of potency: Sumac higher than Shanqui Red higher than Black higher than Mycogen higher than Fontanelle higher than White sorghum. Hyaluronidase inhibition correlate positively with total phenolic content and ferric reducing antioxidant power values for each bran extract. Inhibition is not only due to condensed tannins (proanthocyanidins) because the Black sorghum cultivar lacks condensed tannins but has abundant anthocyanins and other polyphenols
-
Sr2+
0.2 M, about 40% loss of activity
sulfated 2-hydroxyphenyl monolactobioside
-
IC50 is 0.025 mM
sulfated hydroquinone galactoside
2-mercaptoethanol
-
2-mercaptoethanol
Palamneus gravimanus
-
-
6-palmitoyl-L-ascorbic acid
-
0.005 mM, 95% inhibition at pH 7.0
6-palmitoyl-L-ascorbic acid
-
0.005 mM, 93% inhibition at pH 7.0
apigenin
-
strong inhibition
apigenin
-
52% inhibition at 1 mM and 10 mM
aristolochic acid
-
-
aristolochic acid
-
complete inhibition
Ba2+
0.2 M, about 90% loss of activity
beta1,4-galacto-oligosaccharides
-
partially sulfated and non-sulfated forms, especially tri-, tetra-, and pentasaccharides
-
beta1,4-galacto-oligosaccharides
-
partially sulfated and non-sulfated forms, especially tri-, tetra-, and pentasaccharides, IC50 values
-
Ca2+
-
65% residual activity at 50 mM
Ca2+
complete inhibition at 0.2 mM
Ca2+
-
inhibition at 300 mM
Cd2+
0.2 M, complete loss of activity
chondroitin O-sulfate
-
IC50 = 0.00133 mg/ml
chondroitin O-sulfate
-
inhibition between 50-500 ng/ml
chondroitin O-sulfate
-
complete inhibition from 0.012-1.2 mg/ml
Cu2+
-
inhibition reversed by cysteine
Cu2+
0.2 M, about 90% loss of activity
Cu2+
-
complete inhibition at 0.8 mM
Cu2+
-
67% inhibition at 5 mM
curcumin
-
IC50 is 0.057 mM
dermatan O-sulfate
-
IC50 = 0.00133 mg/ml
-
dermatan O-sulfate
-
10% inhibition at 50 ng/ml
-
dermatan sulfate
-
-
dexamethasone
-
DTT
-
-
DTT
Palamneus gravimanus
-
-
EDTA
-
complete inhibition at 10 mM
EDTA
Palamneus gravimanus
-
-
Fe2+
-
77% residual activity at 50 mM
Fe2+
-
complete inhibition at 0.8 mM
Fe3+
-
20% residual activity at 50 mM
Fe3+
-
inhibition reversed by diphosphate
Fe3+
-
complete inhibition at 0.8 mM
glutathione
non-competitive
glutathione
-
non-competitive
glutathione
-
non-competitive
glutathione
-
non-competitive, complete inhibition at 1.8 mg/ml
glutathione
Palamneus gravimanus
-
-
heparan sulfate
-
43% inhibition at 500 ng/ml
heparin
-
90% inhibition at 1.5 mg/ml
heparin
-
inhibition can be prevented by addition of NaCl
heparin
-
inhibitory potency can be regulated by chemical modification, in form of conformational changes, with aldehyde dextran, increase in modification degree decreases the inhibition, best at 70-90% modification, overview
heparin
-
IC50 = 0.00114 mg/ml, non-competitive inhibition; noncompetitive
heparin
-
73% inhibition at 500 ng/ml
heparin
-
58.4% inhibition at 1.2 mg/ml
heparin
Palamneus gravimanus
-
-
heparin
-
65% inhibition at 5 mM
Hg2+
-
moderate inhibition at 20 mM
Hg2+
-
complete inhibition at 0.8 mM
Hg2+
-
43% inhibition at 5 mM
indomethacin
-
IC50 is 0.086 mM
kaempferol
-
36% inhibition at 1 mM
kaempferol
-
50.75% inhibition at 0.2 mM
L-ascorbic acid
-
-
L-ascorbic acid
-
inactive at concentrations less than 100 mM, at pH 5.0
Mg2+
-
46% residual activity at 50 mM
Mg2+
0.2 M, about 20% loss of activity
Mg2+
complete inhibition at 0.2 mM
Mg2+
-
inhibition at 300 mM
N-(4-chlorobenzyl)-1-(4-fluorobenzyl)-1H-indole-3-carboxamide
-
0.05 mM, 66% inhibition at pH 7.0
N-(4-chlorobenzyl)-1-(4-fluorobenzyl)-1H-indole-3-carboxamide
-
0.05 mM, 21% inhibition at pH 7.0
N-(4-fluorobenzyl)-1-benzyl-1H-indole-2-carboxamide
-
0.05 mM, 80% inhibition at pH 7.0
N-(4-fluorobenzyl)-1-benzyl-1H-indole-2-carboxamide
-
0.05 mM, 61% inhibition at pH 7.0
N-acetyl-L-cysteine
non-competitive
N-acetyl-L-cysteine
-
non-competitive
N-acetyl-L-cysteine
-
non-competitive
N-acetyl-L-cysteine
-
non-competitive, complete inhibition at 1.8 mg/ml
NaCl
-
0.5 M causes 92% inhibition
NaCl
1 M NaCl significantly reduces the enzyme activity
NaCl
-
complete but reversible loss of activity above 0.2 M
NaCl
-
sharp decrease of activity above 0.15 M
NaCl
-
complete inhibition at 1 mM
partially sulfated neomycin
-
the non-sulfated neomycin is not inhibitory
-
partially sulfated neomycin
-
the non-sulfated neomycin is not inhibitory
-
partially sulfated planteose
-
the non-sulfated planteose is not inhibitory, IC50 is 0.008 mM
partially sulfated planteose
-
the non-sulfated planteose is not inhibitory, IC50 is 0.005 mM
partially sulfated verbascose
-
2 forms, the non-sulfated verbascose is not inhibitory, IC50 are 0.040 mM and 0.003 mM
-
partially sulfated verbascose
-
2 forms, the non-sulfated verbascose is not inhibitory
-
quercetin
-
54.63% inhibition at 0.2 mM
quercetin
-
complete inhibition
rutin
-
-
rutin
-
61.87% inhibition at 0.2 mM
serum protein
-
inhibition strongly influenced by salts, that in- or decrease the effect
-
serum protein
-
from human, 33.7% inhibition at 1.2 mg/ml
-
sulfated hydroquinone galactoside
-
IC50 is 0.006 mM
sulfated hydroquinone galactoside
-
IC50 is 0.015 mM
Tannic acid
-
IC50 is 0.070 mM
Urea
-
complete inhibition at 10 mM
Urea
Palamneus gravimanus
-
-
Zn2+
-
-
Zn2+
0.2 M, complete loss of activity
Zn2+
-
inhibition at 300 mM
additional information
-
not affected by ascorbic acid, phenylmethylsulfonyl fluoride, dithiothreitol, glutathione (reduced), or L-cysteine
-
additional information
-
enzyme stably covalently linked to activated glycosaminoglycans, such as heparin, dextran and dermatan sulfate, is reduced in its activity and the inhibitory effect of free heparin is increased, while chondroitin sulfate stabilizes the enzyme against heparin inhibition, effect of glycosaminoglycan fragments with different residues, at different pH values, overview
-
additional information
-
iridoids from leaves and stem of malaysian medical plants Rothmannia macrophylla and Saprosma scortechinii are poor inhibitors, e.g. sapromoside A, D, E, G, asperulosidic acid, paederosidic acid, 6-epi-paederosidic acid, methylpaederosidate, 6alpha-hydroxygeniposide, asperuloside, paederoside, macrophylloside, and gardenogenin A and B, overview
-
additional information
-
no inhibition by saccharic acid, poor inhibitors are alpha-D-glucoheptonic-gamma-lactone, D-saccharic-1,4-lactone, L-gulonic-gamma-lactone, D-ribonic-gamma-lactone, and D-gluconic-gamma-lactone
-
additional information
-
inhibition curves, overview
-
additional information
-
not inhibited by gallic acid, methyl gallate, ethyl gallate, propyl gallate, butyl galate, dodecyl gallate, octyl 3-hydroxybenzoate, and octyl 4-hydroxybenzoate
-
additional information
-
at pH 4 bovine serum albumin (BSA) is able to compete with HAase to form electrostatic complexes with hyaluronan, liberating HAase which recovers its catalytic activity, the BSA concentration necessary to prevent the HAase binding is 25times higher at pH 5.25 than at pH 4.0
-
additional information
-
inhibition data for human and bovine enzyme differ, bovine enzyme is not applicable as an alternative to human PH-20
-
additional information
-
aminomethyl indole derivatives with phenyl substitution at position 5 have higher activity. More lipophilic compounds have better inhibition against the hyaluronidase enzyme
-
additional information
the effect of modified di- and trisaccharides on hyaluronidase activity is assessed by capillary electrophoresis-based enzymatic assay. Hyaluronidase is mostly inhibited in a concentration-dependent fashion by a deoxy modification and activated by a methoxy modification. Trisaccharides are more effective on hyaluronidase activity than disaccharides. Position 4 is more favorable for hyaluronidase activity than position 6 and the activity in position 2 is negligible
-
additional information
-
the ethanol extract of of the stem bark of Butea monosperma dose-dependently inhibits enzyme with IC50 of 0.1254 mg/ml
-
additional information
-
the residual activities normalized to 100% at 0 concentrations of Terminalia chebula extract are reduced to 84% at 0.1 mg/ml, 68% at 0.5 mg/ml, 57% at 1 mg/ml, 26% at 1.5 mg/ml, 20% at 3 mg/ml, and 7% at 30 mg/ml
-
additional information
-
blocking of CD44-receptors inhibits the enzyme-induced tubular structure formation of endothelial cells
-
additional information
-
the ethanol extract of of the stem bark of Butea monosperma dose-dependently inhibits enzyme with IC50 of 0.0494 mg/ml
-
additional information
-
ascorbic acid is a poor inhibitor, the plant-derived inhibitors inhibit isozyme NNH1, reduce the local tissue damage, and retard the easy diffusion of systemic toxins and increase survival time, inhibitory potencies, overview
-
additional information
-
the ethanol extract of of the stem bark of Butea monosperma dose-dependently inhibits enzyme with IC50 of 0.012 mg/ml
-
additional information
-
the residual activities normalized to 100% at 0 concentrations of Terminalia chebula extract are reduced to 88% at 0.1 mg/ml, 78% at 0.5 mg/ml, 58 at 1 mg/ml, 49% at 1.5 mg/ml, 29% at 3 mg/ml, and 15% at 30 mg/ml
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.082
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37°C
0.112
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37°C
0.251
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy]butanedioic acid
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37°C
0.092
(2R,3S)-2-hydroxy-2-(4-hydroxybenzyl)-3-[[(2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37°C
0.12
(2R,3S)-2-hydroxy-2-(4-hydroxybenzyl)-3-[[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37°C
0.153
(2R,3S)-3-[[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-2-hydroxy-2-(4-hydroxybenzyl)butanedioic acid
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37°C
0.138
(2R,3S)-3-[[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]oxy]-2-hydroxy-2-(4-hydroxybenzyl)butanedioic acid
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37°C
0.0285
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-21-cyclohexyl-28-hydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.0264
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-23,28-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.0193
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.0364
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.0556
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.052
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.0302
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-22-[[(2Z)-2-methylbut-2-enoyl]oxy]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.0242
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-22-[(2-methylbutanoyl)oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic aci
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.02
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosidur
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.0552
(3beta,16alpha,21beta,22alpha)-16,28-bis(acetyloxy)-22-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.0515
(3beta,16alpha,21beta,22alpha)-16,28-bis(acetyloxy)-22-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.0449
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic a
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.0405
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-22-[[(2E)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosi
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.0368
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosi
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.0297
(3beta,16alpha,21beta,22alpha)-22-(acetyloxy)-16,28-dihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.0387
(3beta,16alpha,21beta,22alpha)-22-(acetyloxy)-16,28-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.0549
(3beta,16alpha,21beta,22alpha)-28-(acetyloxy)-16,22-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.0487
(3beta,16alpha,21beta,22alpha)-28-(acetyloxy)-21-cyclohexyl-16,22-dihydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.0241
(3beta,16alpha,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.0249
(3beta,16alpha,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.0266
(3beta,16alpha,22alpha)-22-(cyclohexyloxy)-16,23,28-trihydroxyolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.0288
(3beta,16alpha,22alpha)-22-(cyclohexyloxy)-16,28-dihydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.21
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl ([1-[2-(benzyloxy)ethenylidene]but-2-yn-1-yl]oxy)ethaneperoxoate
Bos taurus
-
at pH 5.0
0.105
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 11-phenoxyundecaneperoxoate
Bos taurus
-
at pH 5.0
0.037
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 11-[[1-(2-phenylethenylidene)but-2-yn-1-yl]oxy]undecaneperoxoate
Bos taurus
-
at pH 5.0
2.006
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 3-(2-phenylethenylidene)hex-4-yneperoxoate
Bos taurus
-
at pH 5.0
1.38
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl decaneperoxoate
Bos taurus
-
at pH 5.0
0.208
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl dodecaneperoxoate
Bos taurus
-
at pH 5.0
0.057
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl hexadecaneperoxoate
Bos taurus
-
at pH 5.0
0.039
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl octadecaneperoxoate
Bos taurus
-
at pH 5.0
0.071
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl tetradecaneperoxoate
Bos taurus
-
at pH 5.0
0.096
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl tridecaneperoxoate
Bos taurus
-
at pH 5.0
0.58
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl undecaneperoxoate
Bos taurus
-
at pH 5.0
0.188
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl [[1-(2-phenylethenylidene)but-2-yn-1-yl]oxy]ethaneperoxoate
Bos taurus
-
at pH 5.0
0.543
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl [[2-(2-phenylethenylidene)pent-3-yn-1-yl]oxy]ethaneperoxoate
Bos taurus
-
at pH 5.0
0.18 - 0.29
aristolochic acid
0.008 - 0.018
ascorbic acid palmitate
0.525
cimicifugic acid H
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37°C
0.143
cimicifugic acid I
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37°C
0.193
cimicifugic acid J
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37°C
0.0801
clinopodic acid C
Bos taurus
-
in 0.1 M acetate buffer, at 37°C
0.0828
clinopodic acid E
Bos taurus
-
in 0.1 M acetate buffer, at 37°C
0.057
curcumin
Naja naja
-
IC50 is 0.057 mM
0.58
decyl gallate
Bos taurus
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37°C
0.45
disodium cromoglycate
Bos taurus
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37°C
0.144
fukinolic acid
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37°C
0.026
glycyrrhizic acid
Homo sapiens
-
at pH 3.5
0.112
heptyl gallate
Bos taurus
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37°C
0.253
hexyl gallate
Bos taurus
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37°C
0.086
indomethacin
Naja naja
-
IC50 is 0.086 mM
0.378
L-ascorbic acid decanoate
Homo sapiens
-
at pH 3.5
0.076
L-ascorbic acid dodecanoate
Homo sapiens
-
at pH 3.5
0.05
L-ascorbic acid tridecanoate
Homo sapiens
-
at pH 3.5
0.143
L-ascorbic acid undecanoate
Homo sapiens
-
at pH 3.5
0.22
lansiumamide B
Deinagkistrodon acutus
-
pH and temperature not specified in the publication
3.3
lepidepyrone
Bos taurus
-
at 37°C
0.134
lycopic acid A
Bos taurus
-
in 0.1 M acetate buffer, at 37°C
0.141
lycopic acid B
Bos taurus
-
in 0.1 M acetate buffer, at 37°C
0.56
myricetin 3-O-beta-D-glucopyranoside
Naja atra
-
pH and temperature not specified in the publication
0.078
N-(4,6-dimethylpyridin-2-yl)-[5-bromo-1-(4-methyl)indole-3-yl]carboxamide
Bos taurus
-
pH: 7.0
0.046
N-(pyridin-4yl)-[5-bromo-1-(4-fluorobenzyl)indole-3-yl]carboxamide
Bos taurus
-
pH: 7.0
4
N-acetyl-L-cysteine
Bos taurus
-
in 0.2 M sodium acetate buffer pH 5.5 containing 0.15 M NaCl at 37°C
0.167
nonyl gallate
Bos taurus
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37°C
0.902
octyl 3,4-dihydroxybenzoate
Bos taurus
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37°C
0.113
octyl 3,5-dihydroxybenzoate
Bos taurus
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37°C
0.106
octyl gallate
Bos taurus
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37°C
0.005 - 0.008
partially sulfated planteose
0.04
partially sulfated verbascose
Apis mellifera
-
2 forms, the non-sulfated verbascose is not inhibitory, IC50 are 0.040 mM and 0.003 mM
-
0.2401 - 0.545
rosmarinic acid
0.241
schizotenuin A
Bos taurus
-
in 0.1 M acetate buffer, at 37°C
0.573
shomaside A
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37°C
0.43
shomaside B
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37°C
0.663
shomaside C
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37°C
0.658
shomaside D
Bos taurus
-
IC50 above 0.658 mM, in 0.1 mM acetate buffer (pH 3.5), at 37°C
0.79
shomaside E
Bos taurus
-
IC50 above 0.79 mM, in 0.1 mM acetate buffer (pH 3.5), at 37°C
0.025
sulfated 2-hydroxyphenyl monolactobioside
Bos taurus
-
IC50 is 0.025 mM
0.006 - 0.015
sulfated hydroquinone galactoside
0.07
Tannic acid
Naja naja
-
IC50 is 0.070 mM
0.18
aristolochic acid
Deinagkistrodon acutus
-
pH and temperature not specified in the publication
0.29
aristolochic acid
Naja atra
-
pH and temperature not specified in the publication
0.008
ascorbic acid palmitate
Bos taurus
-
pH: 7.0
0.018
ascorbic acid palmitate
Bos taurus
-
pH: 3.5
0.005
partially sulfated planteose
Bos taurus
-
the non-sulfated planteose is not inhibitory, IC50 is 0.005 mM
0.008
partially sulfated planteose
Apis mellifera
-
the non-sulfated planteose is not inhibitory, IC50 is 0.008 mM
0.2401
rosmarinic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37°C
0.309
rosmarinic acid
Bos taurus
-
in 0.1 M acetate buffer, at 37°C
0.545
rosmarinic acid
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37°C
0.006
sulfated hydroquinone galactoside
Apis mellifera
-
IC50 is 0.006 mM
0.015
sulfated hydroquinone galactoside
Bos taurus
-
IC50 is 0.015 mM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.